
Safety Assessment of Trisodium Ethylenediamine Disuccinate and Tetrasodium Iminodisuccinate as Used in Cosmetics


Status: Draft Report for Panel Review
Release Date: September 1, 2022
Panel Meeting Date: September 26-27, 2022

The Expert Panel for Cosmetic Ingredient Safety members are: Chair, Wilma F. Bergfeld, M.D., F.A.C.P.; Donald V. Belsito, M.D.; David E. Cohen, M.D.; Curtis D. Klaassen, Ph.D.; Daniel C. Liebler, Ph.D.; Allan E. Rettie, Ph.D.; David Ross, Ph.D.; Thomas J. Slaga, Ph.D.; Paul W. Snyder, D.V.M., Ph.D.; and Susan C. Tilton, Ph.D. The Cosmetic Ingredient Review (CIR) Executive Director is Bart Heldreth, Ph.D. This safety assessment was prepared by Priya Cherian, Senior Scientific Analyst/Writer, CIR.

SAFETY ASSESSMENT FLOW CHART

INGREDIENT/FAMILY Trisodium Ethylenediamine Disuccinate

MEETING September 2022





Commitment & Credibility since 1976

Memorandum

To: Expert Panel for Cosmetic Ingredient Safety Members and Liaisons
From: Priya Cherian, Senior Scientific Analyst/Writer, CIR
Date: September 1, 2022
Subject: Safety Assessment of Trisodium Ethylenediamine Disuccinate and Tetrasodium Iminodisuccinate as Used in Cosmetics

Enclosed is the Draft Report of the Safety Assessment of Trisodium Ethylenediamine Disuccinate and Tetrasodium Iminodisuccinate as Used in Cosmetics (*report_TrisodiumEthylenediamineDisuccinate_092022*). This is the first time the Expert Panel is reviewing these 2 ingredients. The Scientific Literature Review (SLR) was announced on June 2, 2022. Since the issuing of the SLR, no unpublished data were received.

Comments on the SLR provided by Council (*PCPCcomments_TrisodiumEthylenediamineDisuccinate_092022*), were addressed, as indicated in the responses to these comments (*response-PCPCcomments_TrisodiumEthylenediamineDisuccinate_092022*).

The following documents are also included in this packet.

- 2021 concentration of use data (*data_TrisodiumEthylenediamineDisuccinate_092022*)
- 2022 VCRP frequency of use data (*VCRP_TrisodiumEthylenediamineDisuccinate_092022*)
- report history (*history_TrisodiumEthylenediamineDisuccinate_092022*)
- data profile (*dataprofile_TrisodiumEthylenediamineDisuccinate_092022*)
- search strategy (*search_TrisodiumEthylenediamineDisuccinate_092022*)
- flow chart (*flow_TrisodiumEthylenediamineDisuccinate_092022*)

After reviewing these documents, if the available data are deemed sufficient to make a determination of safety, the Panel should issue a Tentative Report with a safe as used, safe with qualifications, unsafe, or split conclusion, and Discussion items should be identified. If the available data are insufficient, the Panel should issue an Insufficient Data Announcement (IDA), specifying the data needs therein.



Memorandum

TO: Bart Heldreth, Ph.D.
Executive Director - Cosmetic Ingredient Review

FROM: Alexandra Kowcz, MS, MBA
Industry Liaison to the CIR Expert Panel

DATE: July 11, 2022

SUBJECT: Scientific Literature Review: Safety Assessment of Trisodium Ethylenediamine Disuccinate and Tetrasodium Iminodisuccinate as Used in Cosmetics (release date: June 2, 2022)

The Personal Care Products Council respectfully submits the following comments on the scientific literature review, Safety Assessment of Trisodium Ethylenediamine Disuccinate and Tetrasodium Iminodisuccinate as Used in Cosmetics.

Abbreviations – K_{ow} and Log K_{ow} have the same definitions, n-octanol/water partition coefficient. Either one of these should be deleted, or Log K_{ow} should be defined differently.

Toxicokinetics; Summary – Throughout this section and the Summary, it should be made clear that radioactivity was being measured. It was radioactivity from the test substance, not the test substance that was found in the tissues. Based on the information in Table 4, none of these studies determined if the Trisodium Ethylenediamine Disuccinate was metabolized.

Short-Term and Subchronic Oral – Please correct “or signs toxicity” (add “of”)

Short-Term and Subchronic Oral; Summary; Table 6 – In what organ(s) was single cell death and fatty infiltration observed?

DART; Table 6 – For all studies for which zinc measurements were completed, the results should be presented in both the text and table, as zinc deficiency is known to cause developmental toxicity.

DART – Please revise the following because it is likely both male and female offspring were evaluated for developmental toxicity. “Developmental toxicity was evaluated in female Sprague-Dawley rats ...” (add “offspring of”). Please revise “reproductive effects of both male and female Wistar Han rats” to “reproductive effects in both male and female Wistar Han rats”

Dermal Irritation and Sensitization – Please include the number of animals used in the dermal sensitization tests in the text. Please correct: “considered to non-sensitizing” (add “be”)

Summary – The following is not a complete sentence: “In a 28-day oral toxicity assay performed in Wistar rats, Tetrasodium Iminodisuccinate (up to 1000 mg/kg bw/d).” Please correct: “via gavage, or gestation days 6 – 15” (“or” should be “on”). Please indicate the type of cells used in the *in vitro* mammalian chromosome assay of Trisodium Ethylenediamine Disuccinate.

Table 4 – As all the values are doses, please change the column heading from “Vehicle/Concentration” to “Vehicle/Dose”.

Table 4 – More details of the results of the dermal study would be helpful. The study indicated that of the total radioactivity recovered, much represented unabsorbed material from the skin at the treatment site (~40%) and the dermal and chamber washings (~10%). The description of this study (reference 3) also clearly states that metabolites were not measured.

Table 5 – When available, more information about the acute toxicity studies should be presented in Table 5. For example, the dermal studies indicated that there were no deaths and no skin corrosion (1 study) in a study in which the test substance had a pH of 11, and no skin effects (1 study).

Table 6 – In the Procedure column of the first study, it says that there were “two recovery groups” but then it also says there “was a 14-d observation period for all groups”. The 14-day recovery period was only for controls and high dose treated rats. It should be noted that there was a lack of histopathologic changes in the first study, and the decreased motor activity at the high dose was considered the adverse effect. In the last study, in the Procedure column units of mg/kg bw/day should be called “doses” rather than “concentrations”.

Table 7 – The Procedure column of the third study (and probably the fourth study which says the same procedure as the third study was used) indicates that zinc was measured, but the results of the zinc analysis are not stated in the Results column. In the Results column of the dietary study in Sprague-Dawley rats (high concentration 40,000 ppm), it should also be noted that the reference states that because of the reduced food consumption at the higher concentrations it was difficult to determine if the effects were due to treatment or poor nutrition.

Table 9 – Since OECD TG 404 was followed, please note that although the duration of exposure was not stated, the guideline states that exposure is normally for 4 hours.

Trisodium Ethylenediamine Disuccinate - September 2022 meeting – Priya Cherian	
Comment Submitter: Personal Care Products Council	
Date of Submission: July 11, 2022	
Comment	Response/Action
Abbreviations – K _{ow} and Log K _{ow} have the same definitions, n-octanol/water partition coefficient. Either one of these should be deleted, or Log K _{ow} should be defined differently.	Addressed
Toxicokinetics; Summary – Throughout this section and the Summary, it should be made clear that radioactivity was being measured. It was radioactivity from the test substance, not the test substance that was found in the tissues. Based on the information in Table 4, none of these studies determined if the Trisodium Ethylenediamine Disuccinate was metabolized.	Addressed
Short-Term and Subchronic Oral – Please correct “or signs toxicity” (add “of”)	Addressed
Short-Term and Subchronic Oral; Summary; Table 6 – In what organ(s) was single cell death and fatty infiltration observed?	Addressed
DART; Table 6 – For all studies for which zinc measurements were completed, the results should be presented in both the text and table, as zinc deficiency is known to cause developmental toxicity.	Zinc measurements are presented in the table and text in studies where reproductive defects/toxicity were observed
DART – Please revise the following because it is likely both male and female offspring were evaluated for developmental toxicity. “Developmental toxicity was evaluated in female Sprague-Dawley rats ...” (add “offspring of”). Please revise “reproductive effects of both male and female Wistar Han rats” to “reproductive effects in both male and female Wistar Han rats”	Addressed
Dermal Irritation and Sensitization – Please include the number of animals used in the dermal sensitization tests in the text. Please correct: “considered to non-sensitizing” (add “be”)	Details are typically included in the table, and not the text.
Summary – The following is not a complete sentence: “In a 28-day oral toxicity assay performed in Wistar rats, Tetrasodium Iminodisuccinate (up to 1000 mg/kg bw/d).” Please correct: “via gavage, or gestation days 6 – 15” (“or” should be “on”). Please indicate the type of cells used in the <i>in vitro</i> mammalian chromosome assay of Trisodium Ethylenediamine Disuccinate.	Addressed
Table 4 – As all the values are doses, please change the column heading from “Vehicle/Concentration” to “Vehicle/Dose”.	Addressed
Table 4 – More details of the results of the dermal study would be helpful. The study indicated that of the total radioactivity recovered, much represented unabsorbed material from the skin at the treatment site (~40%) and the dermal and chamber washings (~10%). The description of this study (reference 3) also clearly states that metabolites were not measured.	Addressed
Table 5 – When available, more information about the acute toxicity studies should be presented in Table 5. For example, the dermal studies indicated that there were no deaths and no skin corrosion (1 study) in a study in which the test substance had a pH of 11, and no skin effects (1 study).	Addressed
Table 6 – In the Procedure column of the first study, it says that there were “two recovery groups” but then it also says	Addressed

there “was a 14-d observation period for all groups”. The 14-day recovery period was only for controls and high dose treated rats. It should be noted that there was a lack of histopathologic changes in the first study, and the decreased motor activity at the high dose was considered the adverse effect. In the last study, in the Procedure column units of mg/kg bw/day should be called “doses” rather than “concentrations”.	
Table 7 – The Procedure column of the third study (and probably the fourth study which says the same procedure as the third study was used) indicates that zinc was measured, but the results of the zinc analysis are not stated in the Results column. In the Results column of the dietary study in Sprague-Dawley rats (high concentration 40,000 ppm), it should also be noted that the reference states that because of the reduced food consumption at the higher concentrations it was difficult to determine if the effects were due to treatment or poor nutrition.	Addressed
Table 9 – Since OECD TG 404 was followed, please note that although the duration of exposure was not stated, the guideline states that exposure is normally for 4 hours.	Addressed

Trisodium Ethylenediamine Disuccinate and Tetrasodium Iminodisuccinate – Report History

July 2021

- Concentration of use submitted by Personal Care Products Council

June 2022

- SLR posted

July 2022

- Comments on SLR received by Personal Care Products Council

September 2022

- Draft Report evaluated by Expert Panel

Trisodium Ethylenediamine Disuccinate Data Profile – September 2022 – Priya Cherian

				Toxicokinetics			Acute Tox			Repeated Dose Tox			DART		Genotox		Carci		Dermal Irritation			Dermal Sensitization				Ocular Irritation		Clinical Studies	
	Reported Use	Method of Mfg	Impurities	log P/log K _{ow}	Dermal Penetration	ADME	Dermal	Oral	Inhalation	Dermal	Oral	Inhalation	Dermal	Oral	In Vitro	In Vivo	Dermal	Oral	In Vitro	Animal	Human	In Vitro	Animal	Human	Phototoxicity	In Vitro	Animal	Retrospective/Multicenter	Case Reports
Tetrasodium Iminodisuccinate	X		X				X	X			X				X	X				X			X				X		
Trisodium Ethylenediamine Disuccinate	X		X	X	X	X	X	X	X		X			X	X	X				X	X		X	X			X		

* “X” indicates that data were available in a category for the ingredient

Trisodium Ethylenediamine Disuccinate and Tetrasodium Iminodisuccinate – Priya Cherian

Ingredient	CAS #	InfoB	PubMed	TOXNET	FDA	EU	ECHA	IUCLID	SIDS	ECETOC	HPVIS	NICNAS	NTIS	NTP	WHO	FAO	NIOSH	FEMA	Web
Trisodium Ethylenediamine Disuccinate	178949-82-1; 474787-13-8	x	x		x	x	x					x							x
Tetrasodium Iminodisuccinate	144538-83-0	x	x		x	x	x					x							x

Search Strategy

- Search terms listed below were searched in combination with INCI names, CAS numbers, and chemical names
- If information was found, an “x” is noted

Search Terms

- INCI names
 - Tetrasodium Iminodisuccinate
 - Trisodium Ethylenediamine Disuccinate
- CAS numbers
 - 178949-82-1
 - 474787-13-8
 - 144538-83-0
- chemical/technical names
- toxicity
- metabolism
- irritation
- allergy
- eye
- sensitization
- manufacture
- impurities
- cancer
- carcinogenicity
- mutagenicity
- ames
- reproductive
- teratogenicity
- synthesis

LINKS

Search Engines

- Pubmed (- <http://www.ncbi.nlm.nih.gov/pubmed>)
- Toxnet (<https://toxnet.nlm.nih.gov/>); (includes Toxline; HSDB; ChemIDPlus; DART; IRIS; CCRIS; CPDB; GENE-TOX)

appropriate qualifiers are used as necessary

search results are reviewed to identify relevant documents

Pertinent Websites

- wINCI - <http://webdictionary.personalcarecouncil.org>
- FDA databases <http://www.ecfr.gov/cgi-bin/ECFR?page=browse>
- FDA search databases: <http://www.fda.gov/ForIndustry/FDABasicsforIndustry/ucm234631.htm>;
- EAFUS: <http://www.accessdata.fda.gov/scripts/fcn/fcnavigation.cfm?rpt=eafuslisting&displayall=true>
- GRAS listing: <http://www.fda.gov/food/ingredientspackaginglabeling/gras/default.htm>
- SCOGS database: <http://www.fda.gov/food/ingredientspackaginglabeling/gras/scogs/ucm2006852.htm>
- Indirect Food Additives: <http://www.accessdata.fda.gov/scripts/fdcc/?set=IndirectAdditives>
- Drug Approvals and Database: <http://www.fda.gov/Drugs/InformationOnDrugs/default.htm>
- <http://www.fda.gov/downloads/AboutFDA/CentersOffices/CDER/UCM135688.pdf>
- FDA Orange Book: <https://www.fda.gov/Drugs/InformationOnDrugs/ucm129662.htm>
- OTC ingredient list:
<https://www.fda.gov/downloads/aboutfda/centersoffices/officeofmedicalproductsandtobacco/cder/ucm135688.pdf>
- (inactive ingredients approved for drugs: <http://www.accessdata.fda.gov/scripts/cder/iig/>)
- HPVIS (EPA High-Production Volume Info Systems) - <https://ofmext.epa.gov/hpvis/HPVISlogon>
- NIOSH (National Institute for Occupational Safety and Health) - <http://www.cdc.gov/niosh/>
- NTIS (National Technical Information Service) - <http://www.ntis.gov/>
- NTP (National Toxicology Program) - <http://ntp.niehs.nih.gov/>
- Office of Dietary Supplements <https://ods.od.nih.gov/>
- FEMA (Flavor & Extract Manufacturers Association) - http://www.femaflavor.org/search/apachesolr_search/
- EU CosIng database: <http://ec.europa.eu/growth/tools-databases/cosing/>
- ECHA (European Chemicals Agency – REACH dossiers) – <http://echa.europa.eu/information-on-chemicals;jsessionid=A978100B4E4CC39C78C93A851EB3E3C7.live1>
- ECETOC (European Centre for Ecotoxicology and Toxicology of Chemicals) - <http://www.ecetoc.org>
- European Medicines Agency (EMA) - <http://www.ema.europa.eu/ema/>
- IUCLID (International Uniform Chemical Information Database) - <https://iuclid6.echa.europa.eu/search>
- OECD SIDS (Organisation for Economic Co-operation and Development Screening Info Data Sets)-
<http://webnet.oecd.org/hpv/ui/Search.aspx>
- SCCS (Scientific Committee for Consumer Safety) opinions:
http://ec.europa.eu/health/scientific_committees/consumer_safety/opinions/index_en.htm
- NICNAS (Australian National Industrial Chemical Notification and Assessment Scheme)-
<https://www.nicnas.gov.au/>
- International Programme on Chemical Safety <http://www.inchem.org/>
- FAO (Food and Agriculture Organization of the United Nations) - <http://www.fao.org/food/food-safety-quality/scientific-advice/jecfa/jecfa-additives/en/>
- WHO (World Health Organization) technical reports - http://www.who.int/biologicals/technical_report_series/en/
- www.google.com - a general Google search should be performed for additional background information, to identify references that are available, and for other general information

Safety Assessment of Trisodium Ethylenediamine Disuccinate and Tetrasodium Iminodisuccinate as Used in Cosmetics

Status: Draft Report for Panel Review
Release Date: September 1, 2022
Panel Meeting Date: September 26-27, 2022

The Expert Panel for Cosmetic Ingredient Safety members are: Chair, Wilma F. Bergfeld, M.D., F.A.C.P.; Donald V. Belsito, M.D.; David E. Cohen, M.D.; Curtis D. Klaassen, Ph.D.; Daniel C. Liebler, Ph.D.; Allan E. Rettie, Ph.D.; David Ross, Ph.D.; Thomas J. Slaga, Ph.D.; Paul W. Snyder, D.V.M., Ph.D.; and Susan C. Tilton, Ph.D. The Cosmetic Ingredient Review (CIR) Executive Director is Bart Heldreth, Ph.D. This safety assessment was prepared by Priya Cherian, Senior Scientific Analyst/Writer, CIR.

ABBREVIATIONS

CAS	Chemical Abstracts Service
CFR	Code of Federal Regulations
CIR	Cosmetic Ingredient Review
CLP	classification, labeling, and packaging
Council	Personal Care Products Council
CPSC	Consumer Product Safety Commission
DART	Developmental and Reproductive Toxicity
<i>Dictionary</i>	<i>International Cosmetic Ingredient Dictionary and Handbook</i>
ECHA	European Chemicals Agency
EPA	Environmental Protection Agency
EU	European Union
FDA	Food and Drug Administration
HRIPT	human repeated insult patch test
LC ₅₀	median lethal concentration
LD ₅₀	median lethal dose
Log K _{ow}	n-octanol/water partition coefficient
NICNAS	National Industrial Chemicals Notification and Assessment Scheme
NOEL	no-observed-effect-level
NOAEL	no-observed-adverse-effect-level
NR	none reported
OECD	Organisation for Economic Cooperation and Development
Panel	Expert Panel for Cosmetic Ingredient Safety
TG	test guidelines
VCRP	Voluntary Cosmetic Registration Program

INTRODUCTION

This assessment reviews the safety of Tetrasodium Iminodisuccinate and Trisodium Ethylenediamine Disuccinate as used in cosmetic formulations. According to the web-based *International Cosmetic Ingredient Dictionary and Handbook* (wINCI; *Dictionary*), both of these ingredients are reported to function as chelating agents in cosmetics (Table 1).¹

These ingredients are being grouped together due to structural similarities as amine succinate dimers. In 2002, the Expert Panel for Cosmetic Ingredient Safety (Panel) published a safety assessment on EDTA (a structural isomer of Trisodium Ethylenediamine Disuccinate) and its salts.² These ingredients were considered to be safe as used in cosmetics. In 2019, the Panel reaffirmed the original conclusion of safety. The full report on these ingredients can be accessed on the Cosmetic Ingredient Review (CIR) website (<https://www.cir-safety.org/ingredients>).

This safety assessment includes relevant published and unpublished data that are available for each endpoint that is evaluated. Published data are identified by conducting an exhaustive search of the world's literature. A listing of the search engines and websites that are used and the sources that are typically explored, as well as the endpoints that the Panel typically evaluates, is provided on the CIR website (<https://www.cir-safety.org/supplementaldoc/preliminary-search-engines-and-websites>; <https://www.cir-safety.org/supplementaldoc/cir-report-format-outline>). Unpublished data are provided by the cosmetics industry, as well as by other interested parties.

Much of the data included in this safety assessment were found on the European Chemicals Agency (ECHA)³ and National Industrial Chemicals Notification and Assessment Scheme (NICNAS; now known as the Australian Industrial Chemicals Introduction Scheme)^{4,5} websites. Please note that the ECHA and NICNAS websites provide summaries of information generated by industry, and it is those summary data that are reported in this safety assessment when ECHA or NICNAS is cited.

CHEMISTRY

Definition and Structure

The ingredients in this report are structurally related as amine succinate dimers (Figures 1 and 2). The primary structural difference, therein, is the presence of an ethylamine bridge, present only in Trisodium Ethylenediamine Disuccinate. These structural similarities ("disuccinates") confer the ability to act as chelating agents. The definitions of the ingredients included in this review are provided in Table 1.




Figure 1. Tetrasodium Iminodisuccinate




Figure 2. Trisodium Ethylenediamine Disuccinate

The definitions of the ingredients included in this review are provided in Table 1.

Chemical Properties

Both of these ingredients are water-soluble solids. For example, Trisodium Ethylenediamine Disuccinate (CAS Nos.: 178949-82-1; 474787-13-8) is a solid, granular ingredient, that is highly water-soluble, with a reported water solubility of ≥ 1000 g/l (at 20° C and pH 7), and a low octanol/water partition coefficient (-4.7).^{3,5} Other physical and chemical properties of Trisodium Ethylenediamine and Tetrasodium Iminodisuccinate (CAS No.: 144538-83-0) can be found in Table 2.

Method of Manufacture

Method of manufacture data were not found in the published literature, and unpublished data were not submitted.

Impurities

Tetrasodium Iminodisuccinate

A NICNAS safety assessment on Tetrasodium Iminodisuccinate reported a 72.1% purity level for this ingredient.⁴ Impurities/residual monomers present in this ingredient include fumaric acid, disodium salt (5.6%), aspartic acid, disodium salt (10.6%), and water (8.9%).

Trisodium Ethylenediamine Disuccinate

According to a NICNAS safety assessment, Trisodium Ethylenediamine Disuccinate has a purity of 93%.⁵ Impurities/residual monomers of this ingredient were reported to be ethylene dibromide (< 0.0000001%) and aspartic acid (3.95%).

USE

Cosmetic

The safety of the cosmetic ingredients addressed in this assessment is evaluated based on data received from the US Food and Drug Administration (FDA) and the cosmetics industry on the expected use of these ingredients in cosmetics, and does not cover their use in airbrush delivery systems. Data are submitted by the cosmetic industry via the FDA's Voluntary Cosmetic Registration Program (VCRP) database (frequency of use) and in response to a survey conducted by the Personal Care Products Council (Council) (maximum use concentrations). The data are provided by cosmetic product categories, based on 21CFR Part 720. For most cosmetic product categories, 21CFR Part 720 does not indicate type of application and, therefore, airbrush application is not considered. Airbrush delivery systems are within the purview of the US Consumer Product Safety Commission (CPSC), while ingredients, as used in airbrush delivery systems, are within the jurisdiction of the FDA. Airbrush delivery system use for cosmetic application has not been evaluated by the CPSC, nor has the use of cosmetic ingredients in airbrush technology been evaluated by the FDA. Moreover, no consumer habits and practices data or particle size data are publicly available to evaluate the exposure associated with this use type, thereby preempting the ability to evaluate risk or safety.

According to the 2022 VCRP survey data, Trisodium Ethylenediamine Disuccinate is used in 228 formulations (68 leave-on formulations and 160 rinse-off formulations; Table 3) and Tetrasodium Iminodisuccinate is used in 9 formulations (4 leave-on formulations and 5 rinse-off formulations).⁶ The results of the concentration of use survey conducted by the Council in 2021 indicate that the reported maximum concentration of use is 0.64% Trisodium Ethylenediamine Disuccinate in tonics, dressings, and other hair grooming aids; the greatest reported maximum concentration of use in products intended for dermal contact is 0.56% in moisturizing products.⁷ No concentration of use data were reported for Tetrasodium Iminodisuccinate.

Incidental ingestion and mucous membrane exposure may occur as Trisodium Ethylene Disuccinate is reported to be used in lipsticks at 0.01% and in bath soaps and detergents at up to 0.19%. In addition, Trisodium Ethylenediamine Disuccinate is reported to be used in baby products (e.g., baby shampoos at 0.19%).

Trisodium Ethylenediamine Disuccinate is used in cosmetic sprays and could possibly be inhaled (e.g., Trisodium Ethylene Disuccinate is used in pump hair spray formulations at 0.039%). In practice, as stated in the Panel's respiratory exposure resource document (<https://www.cir-safety.org/cir-findings>), most droplets/particles incidentally inhaled from cosmetic sprays would be deposited in the nasopharyngeal and tracheobronchial regions and would not be respirable (i.e., they would not enter the lungs) to any appreciable amount.

Although products containing some of these ingredients may be marketed for use with airbrush delivery systems, this information is not available from the VCRP or the Council survey. Without information regarding the frequency and concentrations of use of these ingredients (and without consumer habits and practices data or particle size data related to this use technology), the data are insufficient to evaluate the exposure resulting from cosmetics applied via airbrush delivery systems.

Both ingredients named in the report are not restricted from use in any way under the rules governing cosmetic products in the European Union.⁸

Non-Cosmetic

Trisodium Ethylenediamine Disuccinate and Tetrasodium Iminodisuccinate are reported to have several industrial uses. These uses include plant protection products and washing and cleaning products (e.g., detergents, stain removers, kitchen

cleaners).^{3,9} Tetrasodium Iminodisuccinate is exempt from the requirement of a tolerance for residues when used as an inert ingredient in antimicrobial pesticide products for which, when ready for use, the end-use concentration does not exceed 5000 ppm Tetrasodium Iminodisuccinate.¹⁰ Trisodium Ethylenediamine Disuccinate is exempt from the requirement of a tolerance for residues when used as an inert ingredient (sequestrant or chelating agent) in pesticide formulations applied to growing crops or to raw agricultural commodities after harvest under Environmental Protection Agency (EPA) regulations.¹¹

TOXICOKINETIC STUDIES

Details regarding the dermal and oral toxicokinetic studies on Trisodium Ethylenediamine Disuccinate summarized below can be found in Table 4.

A dermal toxicokinetic assay was performed in CrI:(WI)BR rats with [¹⁴C]labeled Trisodium Ethylenediamine Disuccinate (4.14 mg/kg bw in males and 5.12 mg/kg bw in females).³ Approximately 11.1% and 5% of the applied dose was absorbed in males and females, respectively. The amount of radioactivity detected in organs ranged from 0 to 1.2%. In an oral toxicokinetic assay, [¹⁴C]labeled Trisodium Ethylenediamine Disuccinate was given to CrI:(WI)BR rats, via gavage. The majority of the radioactivity was excreted (62% in males and 71% in females) via feces within 24 h following administration. The combined mean radioactivity content of blood and tissue was 0.136% and 0.153% of the administered dose in male and female rats, respectively. In a toxicokinetic assay evaluating the distribution of [¹⁴C]labeled Trisodium Ethylenediamine Disuccinate, female Wistar rats were given 2053 mg/kg bw of the test substance (via gavage), and tissues (blood, liver, kidneys, ovaries, and bone marrow) were evaluated at time intervals up to 72 h post-exposure. Radioactivity was detected at low levels in all tissues analyzed, with the highest level found in the kidneys 8 h post-administration (26 µg/g). A similar assay was performed in male Wistar rats. Animals were given [¹⁴C]labeled Trisodium Ethylenediamine Disuccinate at a dose of 2106 mg/kg bw, via gavage. Peak levels of radioactivity in the testes, kidneys, liver, and bone marrow were 6.8, 42, 27, and 37 µg/g tissue, respectively.

TOXICOLOGICAL STUDIES

Acute Toxicity Studies

Details regarding the acute dermal, oral, and inhalation toxicity studies summarized below can be found in Table 5.

The median lethal dose (LD₅₀) was reported to be > 2000 mg/kg bw in an acute dermal toxicity assay performed in rats using Tetrasodium Iminodisuccinate.⁴ Acute dermal LD₅₀s of > 2000 mg/kg bw and > 2640 mg/kg bw were established for rats and rabbits given Trisodium Ethylenediamine Disuccinate, respectively.^{3,5} An LD₅₀ of > 2000 mg/kg bw was established in an acute oral toxicity study evaluating a 20% solution of Tetrasodium Iminodisuccinate in Wistar rats. In acute oral toxicity assays using Trisodium Ethylenediamine Disuccinate performed in Wistar rats and CD-1 rats, the oral LD₅₀s were reported to be > 2000 mg/kg bw and > 2700 mg/kg bw, respectively. In addition, the acute inhalation toxicity potential of Trisodium Ethylenediamine Disuccinate was evaluated in Sprague-Dawley rats via full-body inhalation methods (4-h exposure period). The median lethal concentration was reported to be > 1490 mg/m³ air.

Short-Term and Subchronic Oral Toxicity Studies

Details regarding the short-term and subchronic oral toxicity studies summarized below can be found in Table 6.

In a 28-d oral toxicity assay, Tetrasodium Iminodisuccinate was given to Wistar rats, via gavage, at doses up to 1000 mg/kg bw/d.⁴ A no-observed-effect-level (NOEL) of 200 mg/kg bw/d was established due to lower motor activity observed in high-dose males. In one 14-d study in which male Wistar rats were treated with Trisodium Ethylenediamine Disuccinate (up to 1250 mg/kg bw/d) in the diet, no deaths or signs of toxicity were observed.^{3,5} However, in another 14-d assay in which Wistar rats were given up to 5000 mg/kg bw/d Trisodium Ethylenediamine Disuccinate in the diet, a no-observed-adverse-effect-level (NOAEL) was determined to be 500 mg/kg bw/d, due to clinical signs of toxicity (e.g., loss of body weight, diarrhea, sedation) observed at higher doses. No signs of clinical toxicity were observed in male Wistar rats given up to 400 mg/kg bw/d of a 42.3% aqueous solution of Trisodium Ethylenediamine Disuccinate, in the diet, for 28 d. In a 90-d assay, Wistar Han rats were given the same test substance as above, in the diet, in doses of up to 1000 mg/kg bw/d. The NOAEL was determined to be 300 mg/kg bw/d due to increased incidence of single cell death and fatty infiltration in the pancreas, and decreases in plasma zinc, copper, and magnesium levels at higher dose levels.

DEVELOPMENTAL AND REPRODUCTIVE TOXICITY STUDIES

Details regarding the oral developmental and reproductive toxicity studies on Trisodium Ethylenediamine Disuccinate summarized below can be found in Table 7.

The potential developmental and reproductive toxicity of Trisodium Ethylenediamine Disuccinate was evaluated in several assays performed in rats. In one assay, Sprague-Dawley rats were treated with up to 700 mg/kg bw/d Trisodium Ethylenediamine Disuccinate via gavage.^{3,5} No signs of toxicity were noted in maternal rats, paternal rats, or fetuses. Developmental toxicity was evaluated in Sprague-Dawley rats given up to 994 mg/kg bw/d Trisodium Ethylenediamine Disuccinate on gestation days 6 - 15, via diet. A dose-dependent decrease in blood zinc levels were observed. The NOAEL was determined to be 551 mg/kg bw/d for both maternal and developmental toxicity in this assay due to clinical signs of

toxicity, post implantation losses, and fetus malformation at high doses. However, no signs of maternal or developmental toxicity was observed in an assay performed in female Sprague-Dawley rats given up to 1000 mg/kg bw/d Trisodium Ethylenediamine Disuccinate on gestation days 6 - 15 via gavage. In a different assay performed in female Sprague-Dawley rats, animals were given up to 1000 mg/kg bw/d Trisodium Ethylenediamine Disuccinate, via gavage, or gestation days 6 - 15. No treatment-related, statistically significant changes in hematological parameters (plasma, copper, iron, zinc) were observed. An NOAEL of 400 mg/kg bw/d was established for maternal toxicity, due to clinical signs of toxicity observed at higher doses, and an NOAEL of 1000 mg/kg bw/d was determined for developmental toxicity. Several signs of maternal toxicity (e.g., emaciation, resorptions, decreased weight gain) was observed in female Sprague Dawley rats treated with up to 40,000 ppm Trisodium Ethylenediamine Disuccinate, via the diet, on gestation days 6 - 15. The NOAEL for maternal toxicity in this assay was determined to be 8000 ppm (approximately 530 mg/kg bw/d). In an assay evaluating the reproductive effects in both male and female Wistar Han rats, animals were treated with up to 1000 mg/kg bw/d Trisodium Ethylenediamine Disuccinate, via diet, for 90 d. No effects on the duration of the estrous cycle was observed in females; however, male rats treated with 1000 mg/kg bw/d displayed an increase in the number of abnormal sperm.

GENOTOXICITY STUDIES

Details regarding the in vitro and in vivo genotoxicity studies that are summarized below can be found in Table 8.

No mutagenicity was observed in Ames assays performed on Tetrasodium Iminodisuccinate and Trisodium Ethylenediamine Disuccinate (both tested at up to 5000 µg/plate; with and without metabolic activation).^{3,5} Positive results were observed in an in vitro mammalian chromosome aberration assay on Trisodium Ethylenediamine Disuccinate (up to 5000 µg/plate; 34% aqueous solution), when Chinese hamster ovary cells were incubated without metabolic activation for 42 h, at concentrations as low as 20 µg/ml. However, no mutagenicity was observed in the same assay when metabolic activation was used, or at shorter incubation times. Similarly, no mutagenicity was observed in an in vitro mammalian cell gene mutation assay on Trisodium Ethylenediamine Disuccinate (up to 5028 µg/ml; with and without metabolic activation; 34% aqueous solution). Both Tetrasodium Iminodisuccinate (up to 1500 mg/kg bw; intraperitoneal injection administration) and Trisodium Ethylenediamine Disuccinate (up to 2000 mg/kg bw; 42.3% aqueous solution; gavage administration) were considered to be non-clastogenic in a mammalian erythrocyte micronucleus assay and mammalian bone marrow chromosome aberration assay, respectively.

CARCINOGENICITY STUDIES

Carcinogenicity data were not found in the published literature, and unpublished data were not submitted.

DERMAL IRRITATION AND SENSITIZATION

Details regarding the animal and human dermal irritation and sensitization data that are summarized below can be found in Table 9.

No irritation was observed in a dermal irritation assay evaluating the irritation potential of Tetrasodium Iminodisuccinate in male Himalayan white rabbits.⁴ Two dermal irritation assays were performed using Trisodium Ethylenediamine Disuccinate in New Zealand white rabbits, under semi-occlusive conditions.^{3,5} The test substance was not considered to be irritating in either study. No irritation was observed in a repeat patch test performed in 12 subjects using an aqueous solution of Trisodium Ethylenediamine Disuccinate (up to 29.41%; occlusive conditions; 24-h applications). No sensitization was observed in a guinea pig maximization assay performed using Tetrasodium Iminodisuccinate (1% intradermal injection; 25% dermal induction; 20% dermal challenge).⁴ Dermal sensitization assays were performed in albino Himalayan spotted guinea pigs using either a 50% aqueous solution of Trisodium Ethylenediamine Disuccinate, or 100% Trisodium Ethylenediamine Disuccinate moistened with water (occlusive conditions).^{3,5} Both test substances were considered to be non-sensitizing; however, slight confluent erythema was observed 24 h after the challenge application in one animal treated with 100% Trisodium Ethylenediamine Disuccinate. No irritation or sensitization was observed in an HRIPT performed in 111 subjects using a 5% aqueous solution of Trisodium Ethylenediamine Disuccinate, under occlusive conditions.

OCULAR IRRITATION STUDIES

Animal

Tetrasodium Iminodisuccinate

An ocular irritation assay was performed using Tetrasodium Iminodisuccinate in Himalayan white rabbits (n = 3), according to OECD TG 405.⁴ The test substance was considered to be non-irritating to the eye (mean irritation score of 0). No details regarding this study were provided.

Trisodium Ethylenediamine Disuccinate

In an ocular irritation assay evaluating the irritation potential of Trisodium Ethylenediamine Disuccinate performed according to OECD TG 405, the test substance was instilled into the eyes of 3 New Zealand White rabbits, and the animals were observed for 7 d.^{3,5} The overall irritation score was reported to be 0.56/13, and the test substance was considered to be slightly irritating. In a different ocular irritation assay performed using Trisodium Ethylenediamine Disuccinate according to the same procedures as above, the mean irritation score was reported to be 0/110.³

SUMMARY

The safety of Tetrasodium Iminodisuccinate and Trisodium Ethylenediamine Disuccinate is reviewed in this safety assessment. According to the *Dictionary*, these ingredients are reported to function as chelating agents in cosmetics.

According to 2022 VCRP data, Trisodium Ethylenediamine Disuccinate and Tetrasodium Iminodisuccinate are reported to be used in 228 and 9 total formulations, respectively. The results of the concentration of use survey conducted by the Council indicate Trisodium Ethylenediamine Disuccinate is used at up to 0.64% in tonics, dressings, and other hair grooming aids; the greatest reported maximum concentration of use in products intended for dermal contact is 0.56% in moisturizing products. No concentrations of use were reported for Tetrasodium Iminodisuccinate.

A dermal toxicokinetic assay was performed in CrI:(WI)BR rats using [¹⁴C]labeled Trisodium Ethylenediamine Disuccinate. Approximately 11.1% and 5% of the radioactivity was absorbed in males and females, respectively. In an oral toxicokinetic assay, [¹⁴C] labeled Trisodium Ethylenediamine Disuccinate performed in CrI:(WI)BR rats, the majority of the radioactivity was excreted (62% in males and 71% in females) via feces, within 24 h following administration. In a toxicokinetic assay evaluating the distribution of [¹⁴C]labeled Trisodium Ethylenediamine Disuccinate in female Wistar rats, the test substance was detected at low levels in all tissues analyzed, with the highest level of radioactivity found in the kidneys 8 h post-administration (26 µg/g tissue). A similar assay was performed in male Wistar rats. Peak levels of radioactivity in the testes, kidneys, liver, and bone marrow were 6.8, 42, 27, and 37 µg/g tissue, respectively.

The LD₅₀ was reported to be > 2000 mg/kg bw in an acute dermal toxicity assay performed in rats using Tetrasodium Iminodisuccinate. Acute dermal LD₅₀s of > 2000 mg/kg bw and > 2640 mg/kg bw was established for rats and rabbits given Trisodium Ethylenediamine Disuccinate, respectively. An LD₅₀ of > 2000 mg/kg bw was established in an acute oral toxicity study evaluating a 20% solution of Tetrasodium Iminodisuccinate in Wistar rats. In acute oral toxicity assays using Trisodium Ethylenediamine Disuccinate performed in Wistar rats and CD-1 rats, the oral LD₅₀s were reported to be > 2000 mg/kg bw and > 2700 mg/kg bw, respectively. In addition, the acute inhalation toxicity potential of Trisodium Ethylenediamine Disuccinate was evaluated in Sprague-Dawley rats via full-body inhalation (4-h exposure period) methods. The median lethal concentration was reported to be > 1490 mg/m³ air.

In a 28-d oral toxicity assay, Tetrasodium Iminodisuccinate was given to rats, via gavage, at up to 1000 mg/kg bw/d. An NOEL of 200 mg/kg bw/d was established due to lower motor activity observed in high-dose males. No toxicity was observed in a 14-d oral toxicity assay using Male Wistar rats treated with Trisodium Ethylenediamine Disuccinate (up to 1250 mg/kg bw/d). However, in a different 14-d oral toxicity assay performed in Wistar rats given up to Trisodium Ethylenediamine Disuccinate, the NOAEL was determined to be 500 mg/kg bw/d in this assay due to clinical signs of toxicity observed at higher doses. No signs of clinical toxicity were observed in male Wistar rats given up to 400 mg/kg bw/d of a 42.3% aqueous solution of Trisodium Ethylenediamine Disuccinate, in the diet, for 28 d. In a 90-d assay, Wistar Han rats were given the same test substance as above, in the diet, in doses of up to 1000 mg/kg bw/d. The NOAEL was determined to be 300 mg/kg bw/d due to increased incidence of single cell death, fatty infiltration, and decreases in plasma zinc, copper, and magnesium levels at higher dose levels.

The potential developmental and reproductive toxicity of Trisodium Ethylenediamine Disuccinate was evaluated in several assays performed in rats. No signs of paternal, maternal, or fetal toxicity was observed in an oral reproductive toxicity assay using Sprague-Dawley rats treated with up to 700 mg/kg bw/d Trisodium Ethylenediamine Disuccinate. Reproductive toxicity was evaluated in Sprague-Dawley rats given up to 994 mg/kg bw/d Trisodium Ethylenediamine Disuccinate on gestation days 6 - 15, via diet. The NOAEL was determined to be 551 mg/kg bw/d for both maternal and developmental toxicity. No signs of maternal or reproductive toxicity was observed in an assay performed in female Sprague-Dawley rats given up to 1000 mg/kg bw/d Trisodium Ethylenediamine Disuccinate on gestation days 6 - 15 via gavage. In a different assay performed in female Sprague-Dawley rats, animals were given up to 1000 mg/kg bw/d Trisodium Ethylenediamine Disuccinate, via gavage, on gestation days 6 - 15. An NOAEL of 400 mg/kg bw/d was established for maternal toxicity due to clinical signs of toxicity observed at higher doses and an NOAEL of 1000 mg/kg bw/d was determined for developmental toxicity. Several signs of maternal toxicity were observed in female Sprague Dawley rats treated with up to 40,000 ppm Trisodium Ethylenediamine Disuccinate via the diet, on gestation days 6 - 15. The NOAEL for maternal toxicity in this assay was determined to be 8000 ppm (approximately 530 mg/kg bw/d). In an assay evaluating the reproductive effects in both male and female Wistar Han rats, animals were treated with up to 1000 mg/kg bw/d Trisodium Ethylenediamine Disuccinate, via diet. No effects on the duration of the estrous cycle was observed in females; however, male rats treated with 1000 mg/kg bw/d displayed an increase in the number of abnormal sperm.

No mutagenicity was observed in Ames assays performed on Tetrasodium Iminodisuccinate and Trisodium Ethylenediamine Disuccinate (both at up to 5000 µg/plate; with and without metabolic activation). Positive results were observed in an in vitro mammalian chromosome aberration assay on Trisodium Ethylenediamine Disuccinate (up to 5000 µg/plate; 34% aqueous solution), when Chinese hamster ovary cells were incubated without metabolic activation for 42 h. No mutagenicity was observed in the same assay when metabolic activation was used, or at lower incubation times. Similarly, no mutagenicity was observed in an in vitro mammalian cell gene mutation assay on Trisodium Ethylenediamine Disuccinate (up to 5028 µg/plate; with and without metabolic activation; 34% aqueous solution). Both Tetrasodium Iminodisuccinate (up to 1500 mg/kg bw; intraperitoneal injection administration) and Trisodium Ethylenediamine Disuccinate (up to 2000 mg/kg bw; 42.3% aqueous solution; gavage administration) were considered to be non-clastogenic in a mammalian erythrocyte micronucleus assay and mammalian bone marrow chromosome aberration assay, respectively.

No irritation was observed in a dermal irritation assay evaluating the irritation potential of Tetrasodium Iminodisuccinate in male Himalayan white rabbits. Similarly, no irritation was noted in two dermal irritation assays performed using Trisodium Ethylenediamine Disuccinate in New Zealand white rabbits, under semi-occlusive conditions. No irritation was observed in a repeat patch test performed in 12 subjects using an aqueous solution of Trisodium Ethylenediamine Disuccinate (up to 29.41%; occlusive conditions; 24-h applications). No sensitization was observed in a guinea pig maximization assay performed using Tetrasodium Iminodisuccinate (1% intradermal injection; 25% dermal induction; 20% dermal challenge). Dermal sensitization assays were performed in albino Himalayan spotted guinea pigs using either a 50% aqueous solution of Trisodium Ethylenediamine Disuccinate, or 100% Trisodium Ethylenediamine Disuccinate moistened with water (occlusive conditions). Both test substances were considered to be non-sensitizing; however, slight confluent erythema was observed 24 h after the challenge application in one animal treated with 100% Trisodium Ethylenediamine Disuccinate. No irritation or sensitization was observed in an HRIPT performed in 111 subjects using a 5% aqueous solution of Trisodium Ethylenediamine Disuccinate, under occlusive conditions.

Tetrasodium Iminodisuccinate was considered to be non-irritating in an ocular irritation assay using Himalayan white rabbits. Slight irritation was observed in an ocular irritation assay using Trisodium Ethylenediamine Disuccinate in New Zealand white rabbits; however, in a different ocular irritation assay performed in New Zealand white rabbits, using the same test substance, no irritation was reported.

DISCUSSION

To be developed.

CONCLUSION

To be determined.

TABLES**Table 1. Definitions, structures, and reported functions¹.** CIR STAFF



Ingredient	Definition	Function
Tetrasodium Iminodisuccinate (144538-83-0)	<p>Tetrasodium Iminodisuccinate is the organic compound that conforms to the formula:</p> 	chelating agent
Trisodium Ethylenediamine Disuccinate (178949-82-1; 474787-13-8)	<p>Trisodium Ethylenediamine Disuccinate is the organic compound that conforms to the formula:</p> 	chelating agent

Table 2. Physical and chemical properties

Property	Value	Reference
Tetrasodium Iminodisuccinate		
Physical Form	solid	4
Color	white	4
Melting Point (°C) (est.)	336.12	12
Water Solubility (g/l @ 25°C & pH 13.1)	564	4
Particle Size* (µm)	< 67 - < 281	4
<i>*ingredient particle size does not necessarily translate to final formulation particle size</i>		
Trisodium Ethylenediamine Disuccinate		
Physical Form	solid, granular	3
Density/Specific Gravity (@ 20°C)	1.63	3
Vapor Density (mmHg)	0.014	3
Melting Point (°C)	> 311	3
Water Solubility (g/l @ 20°C & pH 7)	≥ 1000	3
Solubility in Organic Solvents (mg/100 g solvent @ 37 °C)	≤ 0.4	3
log K _{ow}	< -4.7	3
Disassociation Constants (pK _a , pK _b) (@ 20 °C)	7.5, 4	3
Mass median aerodynamic diameter (µm)	50 – 63	3

Table 3. Frequency (2022) and concentration (2021) of use ^{6,7}

	# of Uses	Conc of Use (%)	# of Uses	Conc of Use (%)
	Trisodium Ethylenediamine Disuccinate		Tetrasodium Iminodisuccinate	
Totals*	228	0.0039 – 0.64	9	NR
<i>Duration of Use</i>				
<i>Leave-On</i>	68	0.01 – 0.64	4	NR
<i>Rinse-Off</i>	160	0.0039 – 0.51	5	NR
<i>Diluted for (Bath) Use</i>	NR	NR	NR	NR
<i>Exposure Type</i>				
Eye Area	3	NR	NR	NR
Incidental Ingestion	NR	0.01	NR	NR
Incidental Inhalation-Spray	1; 12 ^a ; 19 ^b	0.039; 0.12 – 0.64 ^b	1 ^b	NR
Incidental Inhalation-Powder	12 ^a	0.06 – 0.19 ^c	NR	NR
Dermal Contact	83	0.06 – 0.56	3	NR
Deodorant (underarm)	NR	NR	NR	NR
Hair - Non-Coloring	75	0.0039 – 0.64	3	NR
Hair-Coloring	66	0.3 – 0.36	3	NR
Nail	NR	NR	NR	NR
Mucous Membrane	20	0.01 – 0.19	NR	NR
Baby Products	3	0.19	NR	NR

*Because each ingredient may be used in cosmetics with multiple exposure types, the sum of all exposure types may not equal the sum of total uses.

^a Not specified whether a spray or a powder, but it is possible the use can be as a spray or a powder, therefore the information is captured in both categories

^b It is possible these products are sprays, but it is not specified whether the reported uses are sprays.

^c It is possible these products are powders, but it is not specified whether the reported uses are powders

NR – none reported

Table 4. Toxicokinetic studies³

Test Substance	Animals	No./Group	Vehicle/Dose	Dose/Protocol	Results
DERMAL					
¹⁴ C-labeled Trisodium Ethylenediamine Disuccinate	CrI: (WI)BR rats	5/sex	water; males: 4.14 mg/kg bw (66.7 µCi/kg bw); females: 5.12 mg/kg bw (84.0 µCi/kg bw)	OECD TG 417; The test substance (0.2 ml) was applied to shaved skin (area of 7.6 cm ²) in a glass chamber for 72 h. Urine, feces, cage washing, and expired air were collected at intervals. Levels of radioactivity were determined in adipose tissue, brain, bone marrow, femur bones, gonads, heart, gastrointestinal tracts, gastrointestinal contents, kidneys, livers, lungs, muscle, pancreas, spleens, carcasses, and skin.	Following the 72-h exposure period, 11.1% of the applied dose was absorbed in males, and 5% of the applied dose was absorbed in females. The total recovery of radioactivity in males and females was 59.1% and 62.8%, respectively. These levels mainly represented unabsorbed test material found at the skin treatment site (~40%) and dermal chamber washings (~10%). The amount of radioactivity detected in organs and tissues ranged from 0 to 1.2% in the male carcass. The combined mean blood and tissue recovery was 2.34% in males and 1.45% in females. Approximately 9% of the applied dose was excreted in males, and about 4% of the applied dose was excreted in females, during the 72-h exposure period.
ORAL					
¹⁴ C-labeled Trisodium Ethylenediamine Disuccinate	CrI: (WI)BR rats	5/sex	water; 2-3 mg/kg bw (approximately 10 µCi/rat)	OECD TG 417; A single dose of the test substance was administered via gavage while in metabolism cages. Urine, feces, cage washes, and expired air were collected at intervals. At study termination (72 h after administration), blood samples were taken, select tissue and gastrointestinal contents were taken, and levels of radioactivity were determined via liquid scintillation counting.	In the first 24 h following administration, approximately 62% and 71% of the radioactivity was excreted in the feces in male and female rats, respectively. After 72 h, approximately 75% was excreted by male and female rats (primarily in the feces, with approximately 5% excretion in expired air and urine. At least 5% of the total administered dose was considered absorbed from the gastrointestinal tract, 72 h after administration. The combined mean radioactivity content of blood and tissue was 0.136% and 0.153% of the administered dose in male and female rats, respectively.
¹⁴ C-labeled Trisodium Ethylenediamine Disuccinate	Wistar rats	27 female rats	water; 2053 mg/kg bw	A single dose of the test substance was given to rats via gavage. Animals were necropsied at 2, 8, 15, 24, 32, 37, 48, 56, or 72 h post-exposure. Radioactivity was measured in the blood, liver, kidneys, ovaries, and bone marrow.	Radioactivity was detected at low levels in all tissues analyzed, peaking within 24-h post-administration. Highest levels of radioactivity were found in the kidney and liver (26 and 16, µg/g tissue, respectively), peaking within 8 h post-administration. Peak levels in the blood, plasma, ovaries, and bone marrow were 13, 9.4, 6.7, and 14 µg/g tissue, respectively.
¹⁴ C-labeled Trisodium Ethylenediamine Disuccinate	Wistar rats	3 male rats/group	water; 2106 mg/kg bw	A single dose of the test substance was given to rats via gavage. Animals were necropsied at 2, 8, 15, 24, 32, 37, 48, 56, or 72 h post-exposure. Radioactivity was measured in the blood, plasma, testes, kidneys, liver, and bone marrow.	Levels of radioactivity peaked in the liver, kidney, testes, and bone marrow between 15 – 32 h post-administration. Peak levels in the testes, kidneys, liver, and bone marrow were 6.8, 42, 27, and 37 µg/g tissue, respectively. Blood and plasma levels were relatively constant during the first 48 h (at around 7 and 11 µg/g tissue, respectively). These levels decreased to 4.5 µg/g by study termination.

OECD TG = Organisation for Economic Cooperation and Development test guidelines

Table 5. Acute toxicity studies

Ingredient	Animals	No./Sex/Group	Vehicle	Concentration/Dose/Protocol	LD ₅₀ /LC ₅₀ /Results	Reference
DERMAL						
Tetrasodium Iminodisuccinate	Wistar rats	3	Water	Animals exposed to test substance (2000 mg/kg bw/d) under semi-occlusive conditions; exposure period length not stated	> 2000 mg/kg bw; no systemic effects or skin corrosivity	⁴
Trisodium Ethylenediamine Disuccinate	Wistar rats	5	Water	OECD TG 402; test substance (2000 mg/kg bw) applied to clipped skin on back of rats; semi-occlusive dressing; 24 h exposure period; 14-d observation period	> 2000 mg/kg bw; no clinical signs of systemic toxicity, irritation at treatment site, body weight changes, macroscopic abnormalities, or deaths	^{3,5}
Trisodium Ethylenediamine Disuccinate	New Zealand White rabbits	5	Water	OECD TG 402; test substance (2640 mg/kg bw) applied to the dorso-lumbar region of rabbits under semi-occlusive conditions; 24 h exposure period; 14-d observation period	> 2640 mg/kg bw; no clinical signs of systemic toxicity, irritation at treatment site, body weight changes, macroscopic abnormalities, or deaths	³
ORAL						
Tetrasodium Iminodisuccinate	Wistar rats	3	NR	OECD TG 423; 20% solution; test substance (2000 mg/kg bw) administered to animals orally (method of oral administration not reported)	> 2000 mg/kg	⁴
Trisodium Ethylenediamine Disuccinate	Wistar rats	5	Water	OECD TG 401; test substance (2000 mg/kg bw) administered to animals via gavage; 14-d observation period	> 2000 mg/kg bw; no body weight changes, deaths, or macroscopic abnormalities	^{3,5}
Trisodium Ethylenediamine Disuccinate	CD-1 rats	5	Water	OECD TG 401; test substance (2700 mg/kg bw) administered to animals via gavage; 14-d observation period	> 2700 mg/kg bw; no deaths observed, pilo-erection in all animals noted for first few hours after dosing, enlarged cervical lymph nodes noted in five males and two females, nephrotic effects noted in several males	³
INHALATION						
Trisodium Ethylenediamine Disuccinate	Sprague-Dawley rats	5	Clean air	OECD TG 401; animals were exposed to air containing 0 or 1490 mg/m ³ Trisodium Ethylenediamine Disuccinate via a whole-body chamber; 4 h exposure period	> 1490 mg/m ³ air	³

LC₅₀ = median lethal concentration; LD₅₀ = median lethal dose; NR = not reported; OECD TG = Organisation for Economic Cooperation and Development test guidelines

Table 6. Repeated dose oral toxicity studies

Test Substance	Animals/Sex/Group	Study Duration	Vehicle	Dose/Concentration/Procedure	Results	Reference
Tetrasodium Iminodisuccinate	Wistar rats (5/sex/group)	28 d	Water	OECD TG 407; animals dosed with the test substance at doses of 0, 40, 200, or 1000 mg/kg bw/d; two recovery groups treated with either 0 or 10,000 mg/kg bw/d; Following the 28-d exposure period (animals dosed 7 d/wk) was a 14-d observation period for control and high-dose rats.	No deaths reported. Lower motor activity was observed in high-dose males. A reduction in levels of alanine aminotransferase was observed in high-dose males, but this effect was not dose-dependent. High-dose recovery animals displayed lower relative thymus weights upon necropsy; however, this effect was not observed in the high dose treatment group. No histopathological changes were noted. An NOEL of 200 mg/kg bw/d was determined due to low motor activity at the highest dose.	⁴
Trisodium Ethylenediamine Disuccinate	Male Wistar rats (5/group)	14 d	Diet	Animals were dosed with 0, 750, 1000, or 1250 mg/kg bw/d via the diet, for 14 d. Observations for clinical toxicity were performed throughout study. Internal organs were macroscopically examined following necropsy.	No deaths or toxicity were observed. The NOAEL was determined to be 1250 mg/kg bw/d.	³
Trisodium Ethylenediamine Disuccinate	Wistar rats (5/sex/group)	14 d	Diet	The test substance was fed in the diet at concentrations of 0, 50, 500, 2500, or 5000 mg/kg bw/d. Clinical signs of toxicity were observed throughout the study. Internal organs were macroscopically examined following necropsy.	Loss of body weight, reduced food and water consumption, diarrhea, and hunched posture, was seen in animals dosed with 2500 mg/kg bw/d and higher. One male treated with 5000 mg/kg bw/d died during the study. Sedation was observed in animals treated with 5000 mg/kg bw/d. No microscopic or macroscopic signs of toxicity were observed. The NOAEL was determined to be 500 mg/kg bw/d.	³
Trisodium Ethylenediamine Disuccinate (42.3% aqueous solution)	Male Wistar Han rats (5/group)	28 d	Diet	OECD TG 407; animals were given the test substance in the diet at doses of 0, 50, 150, 300, or 400 mg/kg bw/d. Animals were observed throughout the study for signs of toxicity. Urine and feces were collected over the last 3 d to analyze mineral content (calcium, sodium, potassium, magnesium, zinc, phosphorous, manganese, and copper). Blood was sampled before study termination. Ophthalmoscopic examinations were performed before study, and on day 21. Macroscopic and microscopic evaluations were performed following study termination.	No deaths were observed throughout the study, and no signs of clinical toxicity or adverse effects were noted upon necropsy. A dose-related, statistically-significant increase in the zinc content of urine was evident; however, this increase was compensated for by a decreased zinc output in feces in the 300 and 400 mg/kg bw/d treated groups. No other dose-dependent, statistically-significant changes in mineral levels were observed. The NOAEL was determined to be 400 mg/kg bw/d.	^{3,5}

Table 6. Repeated dose oral toxicity studies

Test Substance	Animals/Sex/Group	Study Duration	Vehicle	Dose/Concentration/Procedure	Results	Reference
Trisodium Ethylenediamine Disuccinate (42.3% aqueous solution)	Wistar Han rats: -20/sex/group at 0 and 1000 mg/kg bw/d (10/sex/group kept for a 4-wk recovery period) -10/sex/group at 50, 300, and 700 mg/kg bw/d	90 d	Diet	Animals were given the test substance in the diet at doses of 0, 50, 300, 700, or 1000 mg/kg bw/d. Satellite groups of 10 animals/sex were given the control or high-dose diets for 90 d, and allowed to recover for 28 d. Animals were observed for toxicity throughout the study, and blood samples were analyzed at 4 and 13 wk (or 17 wk for the recovery groups). Ophthalmoscopic examinations took place at 4 and 13 wk (and at 17 wk in the recovery groups). Macroscopic and microscopic evaluations were performed following study termination.	No deaths were observed, and no treatment-related abnormalities were observed in ophthalmoscopic data, organ weights, urinalysis, or clinical chemistry. Increased incidence of single cell death and fatty infiltration in the pancreas was observed at 700 mg/kg bw/d and higher. At week 13, in animals treated with 1000 mg/kg bw/d, a significant decrease in plasma zinc levels in male and female animals, were observed, compared to controls. A significant reduction in plasma copper and magnesium levels were observed in male animals treated with 1000 mg/kg bw/d, at week 13, compared to controls. The NOAEL was determined to be 300 mg/kg bw/d. Reproductive toxicity parameters evaluated in this study can be found in Table 7.	^{3,5}

NOEL = no-observed-effect-level; NOAEL = no-observed-adverse-effect-level; OECD TG = Organisation for Economic Cooperation and Development test guidelines

Table 7. Oral developmental and reproductive toxicity studies

Ingredient	Animals/Group	Vehicle	Dose/Concentration	Procedure	Results	Reference
Trisodium Ethylenediamine Disuccinate	Sprague-Dawley rats (25/sex/group)	Water	0, 90, 250, or 700 mg/kg bw/d	Animals were treated with the test substance via gavage for 70 d before mating, and throughout mating, pregnancy, and weaning. Animals were observed for mortality, clinical signs of toxicity, body weight gain, feed consumption, changes in the estrus cycle, precoital index, mating index, fertility, gestation index, number and sex of offspring, litter size and viability, and lactation index. Culling of several of the offspring were performed 4 d after birth, and these offspring were evaluated for external and internal abnormalities, as well as hydrocephaly. Post-necropsy evaluations were performed 28 d after delivery. Reproductive organs were weighed and sperm evaluations were performed.	No signs of developmental or reproductive toxicity were observed in any treated group. Zinc levels in serum were elevated in males in all treatment groups, and in highest-dosed females. The NOAEL was determined to be 700 mg/kg bw/d.	³
Trisodium Ethylenediamine Disuccinate	Female Sprague-Dawley rats (34 rats/group)	Diet	0, 132, 551, or 994 mg/kg bw/d	Pregnant female rats were given the test substance on gestation days 6 to 15. Four rats per group (satellite group) were killed on gestation day 16 for blood analysis of zinc, iron, and copper. The remaining animals were killed on gestation day 20. Animals were observed for gross abnormalities, and the uterus was examined for fetuses, implantations, resorptions, and corpora lutea. Fetuses were weighed and examined.	Reduced body weight gain and food consumption was observed in maternal rats treated with 994 mg/kg bw/d. A dose-dependent decrease in blood zinc levels was observed (statistically significant at doses of 551 and 994 mg/kg bw/d). Mean gravid uterine weights were significantly reduced in animals treated with 994 mg/kg bw/d. A statistically significant increase in post-implantation losses was observed in the high-dose group, reducing the number of live male fetuses. Fetuses in the high-dose group had a range of external, visceral, and/or skeletal malformations and developmental variations. The NOAEL was determined to be 551 mg/kg bw/d for both maternal and developmental toxicity.	^{3,5}
Trisodium Ethylenediamine Disuccinate	Female Sprague-Dawley rats (9/group)	Water	0, 50, 200, 400, 600, or 1000 mg/kg bw/d	Pregnant females were given the test substance via gavage on gestation days 6-15. Three rats from each group were killed on gestation day 16, and blood samples were analyzed for zinc, copper, and iron. Remaining animals were killed on gestation day 20, and evaluated for gross abnormalities, viable fetuses, resorptions, implantations, and corpora lutea. Fetuses were weighed and examined for soft-tissue and skeletal effects.	No evidence of treatment-related maternal or developmental toxicity was observed. The maternal and developmental NOAEL was determined to be 1000 mg/kg bw/d.	³
Trisodium Ethylenediamine Disuccinate	Female Sprague-Dawley rats (36/group)	Water	0, 50, 400, or 1000 mg/kg bw/d	Animals treated according to the same procedure as above; however, 6 animals/group were killed on gestation day 16	Rats treated with 1000 mg/kg bw/d displayed reduced carcass weight, a decrease in food consumption during treatment period, increased incidence of soft stools, and decreased defecation. No treatment-related statistically significant changes in plasma, copper, iron, or zinc levels were observed. No differences were noted in treatment and control groups regarding implantations, number of fetuses, post-implantation losses, or fetal body weights. Various skeletal defects were observed in fetuses of dams treated with 1000 mg/kg bw/d (presacral vertebrae, unossified sternbrae, 7 th cervical rib). These variations were interpreted as evidence of developmental delay, and not as permanent malformations. An NOAEL of 400 mg/kg bw/d was determined for maternal toxicity, and an NOAEL of 1000 mg/kg bw/d was determined for developmental toxicity.	^{3,5}

Table 7. Oral developmental and reproductive toxicity studies

Ingredient	Animals/Group	Vehicle	Dose/Concentration	Procedure	Results	Reference
Trisodium Ethylenediamine Disuccinate	Female Sprague-Dawley rats (5/group)	Diet	0, 2000, 8000, 16,000, 24,000, or 40,000 ppm The approximate intake levels at 8000, 16,000, 24,000, and 40,000 ppm were 530, 981, 830, and 1029 mg/kg bw, respectively (intake levels corresponding to the 2000 ppm concentration were not provided)	Pregnant rats were given the test substance via diet on gestation days 6-15. Clinical signs of toxicity were evaluated throughout treatment period. After 20 d, animals were killed, and uterine examinations were performed.	Two animals in the highest dose group died. Reduced food consumption and decreased weight gain was noted in animals treated with 16,000 ppm and above. Emaciation was noted in animals treated with 24,000 ppm and above. One animal treated with 40,000 ppm produced no feces. No viable fetuses were observed in animals treated with 40,000 ppm. The mean number of live fetuses per animal was reduced to 5 in animals treated with 24,000 ppm, compared to 14.5 in the control group. Gravid uterine weights were reduced at 16,000 and 24,000 ppm. The mean number of total resorptions in animals treated with 0, 2000, 8000, 16,000, and 24,000 ppm was 0.5, 0.2, 1.6, 0.8, and 7.67, respectively. Late resorptions were observed in animals treated with 24,000 and 40,000 ppm. Post- implantation losses were 14-fold higher in animals treated with 24,000 ppm, compared to controls. Study authors stated that because of the reduced food consumption, it was difficult to determine if effects were related to treatment or poor nutrition. The NOAEL for maternal toxicity was determined to be 8000 ppm (approximately 530 mg/kg bw/d).	³
Trisodium Ethylenediamine Disuccinate	Wistar Han rats: -20/sex/group at 0 and 1000 mg/kg bw/d (10/sex/group kept for a 4-wk recovery period) -10/sex/group at 50, 300, and 700 mg/kg bw/d	Diet	0, 50, 300, 700, or 1000 mg/kg bw/d	Animals (10/sex) were given the test substance in the diet for 90 d. Satellite groups of 10 animals/sex were given the control or high-dose diets for 90 d, and allowed to recover for 28 d. Estrous cycle duration was determined in female rats over the last month of the study. A sperm analysis and histopathological analysis of the testes were performed at study termination.	No adverse effects on the duration of the estrous cycle were observed at any dose level. In males treated with 1000 mg/kg bw/d, an increase in the number of abnormal sperm (but no effects on motility or concentration), atypical residual bodies of minimal severity and incidence, were observed. Results regarding other subchronic toxicity parameters evaluated in this study can be found in Table 6.	³

NOAEL = no-observed-adverse-effect-level; OECD TG = Organisation for Economic Cooperation and Development test guidelines

Table 8. Genotoxicity studies

Test Article	Concentration/Dose	Vehicle	Test System	Procedure	Results	Reference
IN VITRO						
Tetrasodium Iminodisuccinate	50 – 5000 µg/plate	NR	<i>Salmonella typhimurium</i> : TA1535, TA1537, TA98, TA100, TA102	OECD TG 471; Ames assay performed with and without metabolic activation	Non-mutagenic	4
Trisodium Ethylenediamine Disuccinate (34% aqueous solution)	0, 33, 100, 333, 1000, 3333, 5000 µg/plate	Water	<i>S. typhimurium</i> : TA98, TA100, TA1535, TA1537, TA1538, <i>Escherchia coli</i> : WP2 (pKM101) and WP2 uvrA (pKM101)	OECD TG 471; Ames assay performed with and without metabolic activation	Non-mutagenic	3,5
Trisodium Ethylenediamine Disuccinate	0, 50, 150, 500, 1500 and 5000 µg/plate	Water	<i>S. typhimurium</i> : TA1535, TA1537, TA1538, TA98, TA100	OECD TG 471: Ames assay performed with and without metabolic activation	Non-mutagenic	3
Trisodium Ethylenediamine Disuccinate (34% aqueous solution)	0, 5, 10, 20, 40, 79, 157, 313, 625, 1250, 2500 and 5000 µg/ml	Water	Chinese hamster ovary cells	OECD TG 473; In vitro mammalian chromosome aberration assay performed with and without metabolic activation; cells incubated without metabolic activation for 6, 18, or 42 h, and with metabolic activation for 6 h	No statistically significant increases in structural or numerical aberrations were observed in 6 and 18 h treatments. A statistically significant increase in structural aberrations at 40 µg/ml in the 42-h study ($p < 0.025$) (performed without metabolic activation), and statistically significant dose response ($p < 0.05$), was observed. In the 42-h treatment study, there was also a statistically significant increase in numerical chromosome aberrations with 20 and 40 µg/ml ($p < 0.05$) (performed without metabolic activation).	3,5
Trisodium Ethylene diamine Disuccinate (34% aqueous solution)	0, 2765, 3017, 3268, 3519, 3771, 4022, 4273, 4524, 4776, and 5028 µg/ml	Culture medium	Mouse lymphoma L5178Y cells	OECD TG 472: In vitro mammalian cell gene mutation test performed with and without metabolic activation	Non-mutagenic	3,5
IN VIVO						
Tetrasodium Iminodisuccinate	0 – 1500 mg/kg bw	Water	Mouse/HSD/Win: NMRI (5/sex/group)	OECD TG 474: Mammalian erythrocyte micronucleus test; singular intraperitoneal injection	Non-clastogenic	4
Trisodium Ethylenediamine Disuccinate (42.3% aqueous solution)	0, 200, 670, 2000 mg/kg bw	Water	Sprague-Dawley rats (15-20/sex/group)	OECD TG 475; Mammalian bone marrow chromosome aberration assay; animals given a singular dose of the test substance via gavage	Non-clastogenic	3,5

OECD TG = Organisation for Economic Cooperation and Development test guidelines

Table 9. Dermal irritation and sensitization

Test Article	Concentration/Dose	Test Population	Procedure	Results	Reference
IRRITATION					
ANIMAL					
Tetrasodium Iminodisuccinate in water	NR	3 male Himalayan white rabbits	OECD TG 404; Animals exposed to test substance under semi-occlusive condition; observation period of 3 d; 4-h exposure period	Non-irritating	4
Trisodium Ethylenediamine Disuccinate	500 mg; area of 6 cm ²	3 New Zealand white rabbits	OECD TG 404; test substance moistened with water was applied to the intact skin of the dorsal trunk region, under semi-occlusive conditions; 4-h exposure period; site evaluated 1, 24, 48, and 72 h after patch removal	Non-irritating	3,5
Trisodium Ethylenediamine Disuccinate	660 mg; area of 5 cm ²	3 New Zealand white rabbits	OECD TG 404; test substance moistened with water was applied to the intact skin of the dorsal trunk region, under semi-occlusive conditions; 4-h exposure period; site evaluated 30 min, 24, 48, and 72 h after patch removal	Non-irritating	3

Table 9. Dermal irritation and sensitization

Test Article	Concentration/Dose	Test Population	Procedure	Results	Reference
HUMAN					
Trisodium Ethylenediamine Disuccinate	0.4 ml; 2.94, 14.7, and 29.41% aq.	12 subjects	Repeat patch test; patches applied on Friday, Monday, and Wednesday (24-h applications; occlusive conditions), leaving at least 24 h after removal of previous patch; sites evaluated before each patch application, and 24 h after removal of third patch	Non-irritating	³
SENSITIZATION					
ANIMAL					
Tetrasodium Iminodisuccinate	intradermal injection: 1%; topical induction: 25%; topical challenge: 20%	Guinea pig/Hsd Poc:DH (20 in test group; 10 in control group)	Guinea pig maximization test performed according to OECD TG 406; no details provided	Non-sensitizing	⁴
Trisodium Ethylenediamine Disuccinate	50% aq. for induction and challenge; 500 mg	Albino Himalayan spotted guinea pigs (10/sex/group for treated groups; 5/sex for control group)	OECD TG 406, modified Buehler assay; animals exposed to the test substance, on clipped shoulder region, for 6 h, under occlusive conditions. Two more applications were performed at 7-d intervals. After a 2-wk non-treatment period, animals were exposed to a challenge dose (occlusive application for 6 h), and observed for 48 h. Control animals received the challenge dose only.	Non-sensitizing	^{3,5}
Trisodium Ethylenediamine Disuccinate	100%; 500 mg	Albino Himalayan spotted guinea pigs (10/sex/group for treated groups; 5/sex for control group)	OECD TG 406, modified Buehler assay; animals exposed to the test substance moistened with water, on clipped shoulder region, for 6 h, under occlusive conditions. Two more applications were performed at 7-d intervals. After a 2-wk non-treatment period, animals were exposed to a 100% challenge dose (occlusive application for 6 h), and observed for 48 h. Test sites were re-challenged 7 d later. Control animals received a single challenge dose only.	8/9 tested animals showed slight patchy erythema at 24 h following 1 st challenge, and 15 animals showed slight patchy erythema 24 h after 1 st challenge 9/10 and 3/10 negative controls showed slight patchy erythema 24 h after challenge and re-challenge, respectively One animal in the treated group was found dead on day 20, but cause of death was undetermined Slight confluent erythema was observed 24 h after challenge application in one animal. The test substance was considered to be non-sensitizing by EU CLP regulation.	^{3,5}
HUMAN					
Trisodium Ethylenediamine Disuccinate	5% aqueous	111 subjects	The induction phase consisted of 9 24-h applications, under occlusive patches, over a 3-wk period. Between 12-20 d after the last induction exposure, a challenge dose of the same test substance was applied to the same area, under occlusive conditions, for 24 h. Test areas were examined 48 and 96 h after application of challenge dose.	Non-irritating and non-sensitizing	^{3,4}

CLP = classification, labeling, and packaging; EU = European Union; NR = not reported; OECD TG = Organisation for Economic Cooperation and Development test guidelines

REFERENCES

1. Nikitakis J, Kowcz A. wINCI: *International Cosmetic Ingredient Dictionary and Handbook*. <http://webdictionary.personalcarecouncil.org/jsp/Home.jsp>. Washington, DC: Personal Care Products Council. Last Updated 2022. Accessed March 2, 2022.
2. Andersen FA (ed). Final report on the safety assessment of EDTA, Calcium Disodium EDTA, Diammonium EDTA, Dipotassium EDTA, Disodium EDTA, TEA-EDTA, Tetrasodium EDTA, Tripotassium EDTA, Trisodium EDTA, HEDTA, and Trisodium HEDTA. *Int J Toxicol*. 2002;21 Suppl 2:95-142.
3. European Chemicals Agency (ECHA). L-Aspartic acid, N,N'-1,2-ethanediybis-, sodium salt (1:3). <https://iuclid6.echa.europa.eu/mt/web/guest/registration-dossier/-/registered-dossier/32515/4/2>. Last Updated 2022. Accessed March 2, 2022.
4. National Industrial Chemicals Notification and Assessment Scheme (NICNAS). Full Public Report: Aspartic acid, N-(1,2-dicarboxyethyl)-, tetrasodium salt. <https://www.industrialchemicals.gov.au/sites/default/files/EX45%20Public%20Report%20PDF.pdf?msclid=e49b287acfd311ecacfbe9fe8a623355>. Last Updated 2022. Accessed May 9, 2022.
5. National Industrial Chemicals Notification and Assessment Scheme (NICNAS). Full Public Report: Trisodium Ethylene Diamine Disuccinate. <https://www.industrialchemicals.gov.au/sites/default/files/STD1044%20Public%20Report%20PDF.pdf>. Last Updated 2022. Accessed May 9, 2022.
6. US Food and Drug Administration (FDA) Center for Food Safety & Applied Nutrition (CFSAN). 2022. Voluntary Cosmetic Registration Program - Frequency of Use of Cosmetic Ingredients. (Obtained under the Freedom of Information Act from CFSAN; requested as "Frequency of Use Data" January 4, 2022; received January 11, 2022).
7. Personal Care Products Council. 2021. Concentration of Use by FDA Product Category: Trisodium Ethylenediamine Disuccinate. Unpublished data submitted to Personal Care Products Council on July 7, 2021.
8. European Commission. Cosmetic Regulation No. 1223/2009 Annex III. https://ec.europa.eu/growth/tools-databases/cosing/index.cfm?fuseaction=search.results&annex_v2=III&search. Last Updated 2021. Accessed March 2, 2022.
9. Chen Y, Zhang G, Shi Q, Yang S, Liu D. Utilization of tetrasodium iminodisuccinate to eliminate the adverse effect of serpentine on the flotation of pyrite. *Minerals Engineering*. 2020;150.
10. Environmental Protection Agency. 2018. Aspartic Acid, N-(1,2-dicarboxyethyl)-, Tetrasodium Salt; Exemption From the Requirement of a Tolerance. Environmental Protection Agency, ed.
11. Environmental Protection Agency. 2011. (S,S)-Ethylenediamine Disuccinic Acid Trisodium Salt; Exemption From the Requirement of a Tolerance. Environmental Protection Agency, ed.
12. United States Environmental Protection Agency. 2022. Estimation Programs Interface Suite™ for Microsoft® Windows, v 4.11. Washington, D.C.

2022 Priorities**Concentration of Use by FDA Product Category – Trisodium Ethylenediamine Disuccinate and Tetrasodium Iminodisuccinate***

Ingredient	Product Category	Maximum Concentration of Use
Trisodium Ethylenediamine Disuccinate	Baby shampoos	0.19%
Trisodium Ethylenediamine Disuccinate	Hair conditioners	0.0039%
Trisodium Ethylenediamine Disuccinate	Hair sprays Pump spray	0.039%
Trisodium Ethylenediamine Disuccinate	Shampoos (noncoloring)	0.12-0.51%
Trisodium Ethylenediamine Disuccinate	Tonics, dressings, and other hair grooming aids	0.34-0.64%
Trisodium Ethylenediamine Disuccinate	Hair rinses (coloring)	0.3%
Trisodium Ethylenediamine Disuccinate	Hair shampoos (coloring)	0.36%
Trisodium Ethylenediamine Disuccinate	Lipstick	0.01%
Trisodium Ethylenediamine Disuccinate	Bath soaps and detergents	0.12-0.19%
Trisodium Ethylenediamine Disuccinate	Skin cleansing (cold creams, cleansing lotions, liquids, and pads)	0.093—0.14%
Trisodium Ethylenediamine Disuccinate	Face and neck products Not spray	0.06-0.08%
Trisodium Ethylenediamine Disuccinate	Body and hand products Not spray	0.078-0.19%
Trisodium Ethylenediamine Disuccinate	Moisturizing products Not spray	0.12-0.56%
Trisodium Ethylenediamine Disuccinate	Night products Not spray	0.074%
Trisodium Ethylenediamine Disuccinate	Paste masks and mud packs	0.063%
Trisodium Ethylenediamine Disuccinate	Skin fresheners	0.12%
Trisodium Ethylenediamine Disuccinate	Other skin care preparations	0.074%
Trisodium Ethylenediamine Disuccinate	Suntan products Not spray	0.2%

*Ingredients included in the title of the table but not found in the table were included in the concentration of use survey, but no uses were reported.

Information collected in 2021
Table prepared: July 7, 2021

2022 FDA VCRP: Trisodium Ethylenediamine Dissuccinate and Tetrasodium IminodisuccinateTrisodium Ethylenediamine Disuccinate

Baby Shampoos	1
Other Baby Products	2
Eye Lotion	1
Other Eye Makeup Preparations	2
Cologne and Toilet waters	1
Hair Conditioner	3
Shampoos (non-coloring)	62
Tonics, Dressings, and Other Hair Grooming Aids	7
Other Hair Preparations	2
Hair Dyes and Colors (all types requiring caution statements and patch tests)	66
Blushers (all types)	3
Foundations	16
Makeup Bases	3
Other Makeup Preparations	5
Bath Soaps and Detergents	9
Douches	4
Other Personal Cleanliness Products	7
Other Shaving Preparation Products	1
Cleansing	5
Face and Neck (exc shave)	11
Body and Hand (exc shave)	1
Moisturizing	9
Night	3
Paste Masks (mud packs)	2
Other Skin Care Preps	2

Total: 228

Tetrasodium Iminodisuccinate

Hair Conditioner	2
Other Hair Preparations	1
Hair Dyes and Colors (all types requiring caution statements and patch tests)	3
Aftershave Lotion	1
Moisturizing	1
Other Skin Care Preps	1

Total: 9